Pipeline
The Science
About us
Investors

Hit enter to search or ESC to close

Alterity PBT434 Poster Presented at 2019 MDS Congress

October 3, 2019August 16, 2022 Alterity Therapeutics

Alterity PBT434 Poster – MDS 2019 Congress

2019

Post navigation

Alterity presents clinical data on PBT434 at the 2019 MDS Congress

Quarterly Cash Flow Report

Related Posts

Alterity presents clinical data on PBT434 at the 2019 MDS Congress

September 25, 2019August 16, 2022

Prana Announces Successful Phase 2 Results in Huntington Disease Trial

February 18, 2014August 16, 2022

Appendix 4C – Q3 FY23 Quarterly Cash Flow Report

April 27, 2023May 23, 2023

Recent Posts

Alterity Therapeutics Issues Shareholder Newsletter Highlighting Pipeline Advances and Key Upcoming Milestones
Alterity Therapeutics Completes Last Patient Visit in ATH434-201 Phase 2 Clinical Trial in Early-Stage Multiple System Atrophy
Chairman’s Address 2024 Annual General Meeting
AGM 2024 Presentation
Alterity Therapeutics Announces Presentation on Tracking the Progression of Multiple System Atrophy at International Symposium

Recent Comments

Archives

Archives

Categories

ASX Announcements
Chairman's Address
Investor Announcement

Tags

2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023

About us

We exist to create an alternate future for people living with neurodegenerative diseases. An alternate, healthier life. We’re here to disrupt the trajectory the world has come to accept for people with these diseases.
Improving lives.

LinkedIn
Facebook
X

Pipeline
The Science
About us
Investors
News

Careers
Privacy Policy

Copyright © Alterity Therapeutics. ABN 37 080 699 065